



**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
1635

In Re Application Of: Philip Gotwals, et al.

RECEIVED  
APR 24 2001  
TECH CENTER  
Group Art Unit  
1635

Serial No.  
09/423,018

Filing Date  
October 12, 2000

Examiner

Title:

**Type II TGF-Beta Receptor/Immunoglobulin Constant Region Fusion Proteins**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 02-2327 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. \_\_\_\_\_) on \_\_\_\_\_ (Date).

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

\*This certificate may only be used if paying by deposit account.

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on April 18, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

\_\_\_\_\_  
Signature of Person Mailing Correspondence

Andrea Ritchie  
Typed or Printed Name of Person Mailing Correspondence

\_\_\_\_\_  
Signature

Dated: April 18, 2001

Niki D. Cox, Esq.  
Reg. No. 42,446  
BIOGEN, INC.  
14 Cambridge Center  
Cambridge, MA 02142  
(617) 679-2079 (Direct Dial)  
(617) 679-2838

CC:

GAU-1635

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Doc. No.  
A018 US

**RECEIVED**

APR 24 2001

TECH CENTER 1600/2900

In Re Application Of: Philip Gotwals, et al.

APR 23 2001

**U.S. PATENT & TRADEMARK OFFICE**

Serial No.

423,018

Filing Date

October 12, 2000

Examiner

Group Art Unit

1635

Title:

**Type II TGF-Beta Receptor/Immunoglobulin Constant Region Fusion Proteins**

Address to:

**Assistant Commissioner for Patents  
Washington, D.C. 20231**

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

**OR**

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).